158 related articles for article (PubMed ID: 16202062)
21. Post-transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for high-risk acute myeloid leukaemia.
Oshikawa G; Kakihana K; Saito M; Aoki J; Najima Y; Kobayashi T; Doki N; Sakamaki H; Ohashi K
Br J Haematol; 2015 Jun; 169(5):756-9. PubMed ID: 25522128
[No Abstract] [Full Text] [Related]
22. Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocytic leukemia.
Breccia M; Cimino G; Diverio D; Gentilini F; Mandelli F; Lo Coco F
Haematologica; 2007 Sep; 92(9):1273-4. PubMed ID: 17768126
[TBL] [Abstract][Full Text] [Related]
23. [Gemtuzumab ozogamicin and targeted cancer therapy].
Imaizumi M
Nihon Yakurigaku Zasshi; 2004 Jul; 124(1):25-9. PubMed ID: 15226619
[TBL] [Abstract][Full Text] [Related]
24. Acute and long-term toxicities associated with gemtuzumab ozogamicin (Mylotarg) therapy of acute myeloid leukemia.
Leopold LH; Berger MS; Feingold J
Clin Lymphoma; 2002 Mar; 2 Suppl 1():S29-34. PubMed ID: 11970768
[TBL] [Abstract][Full Text] [Related]
25. Gemtuzumab ozogamicin in combination with attenuated doses of standard induction chemotherapy can successfully induce complete remission without increasing toxicity in patients with acute myeloid leukemia aged 55 or older.
Eom KS; Kim HJ; Min WS; Lee S; Min CK; Cho BS; Kim SY; Kim YJ; Lee DG; Choi SM; Cho SG; Kim DW; Lee JW; Shin WS; Kim CC
Eur J Haematol; 2007 Nov; 79(5):398-404. PubMed ID: 17916082
[TBL] [Abstract][Full Text] [Related]
26. Sensorimotor peripheral neuropathy in an elderly AML patient in complete remission while receiving gemtuzumab ozogamicin as maintenance therapy.
Romani C; Murru R; Adamo F; Di Tucci A; Sabiu D; Casula P; Angelucci E
Ann Hematol; 2006 Jun; 85(6):411-2. PubMed ID: 16538500
[No Abstract] [Full Text] [Related]
27. Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia.
Giles FJ
Expert Rev Anticancer Ther; 2002 Dec; 2(6):630-40. PubMed ID: 12503209
[TBL] [Abstract][Full Text] [Related]
28. The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison.
Burnett AK; Hills RK; Hunter AE; Milligan D; Kell WJ; Wheatley K; Yin J; McMullin MF; Dignum H; Bowen D; Russell NH;
Leukemia; 2013 Jan; 27(1):75-81. PubMed ID: 22964882
[TBL] [Abstract][Full Text] [Related]
29. Molecular response in two children with relapsed acute myeloid leukemia treated with a combination of gemtuzumab ozogamicin and cytarabine.
Brethon B; Auvrignon A; Cayuela JM; Lapillonne H; Leverger G; Baruchel A
Haematologica; 2006 Mar; 91(3):419-21. PubMed ID: 16531270
[TBL] [Abstract][Full Text] [Related]
30. Re-administration of a combination of chemotherapy + Gemtuzumab at relapse in CD33+ AML patient allows to second remission and is feasible without extra toxicity.
Chevallier P; Touzeau C; Ayari S; Guillaume T; Harousseau JL; Delaunay J
Leuk Res; 2008 Aug; 32(8):1321-2. PubMed ID: 18029013
[TBL] [Abstract][Full Text] [Related]
31. Possible association between Budd-Chiari Syndrome and gemtuzumab ozogamicin treatment in a patient with refractory acute myelogenous leukemia.
Kurt M; Shorbagi A; Altundag K; Elkiran T; Güllü I; Kansu E
Am J Hematol; 2005 Nov; 80(3):213-5. PubMed ID: 16247755
[TBL] [Abstract][Full Text] [Related]
32. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence.
Larson RA; Sievers EL; Stadtmauer EA; Löwenberg B; Estey EH; Dombret H; Theobald M; Voliotis D; Bennett JM; Richie M; Leopold LH; Berger MS; Sherman ML; Loken MR; van Dongen JJ; Bernstein ID; Appelbaum FR
Cancer; 2005 Oct; 104(7):1442-52. PubMed ID: 16116598
[TBL] [Abstract][Full Text] [Related]
33. Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19).
Amadori S; Suciu S; Selleslag D; Stasi R; Alimena G; Baila L; Rizzoli V; Borlenghi E; Gaidano G; Magro D; Torelli G; Muus P; Venditti A; Cacciola E; Lauria F; Vignetti M; de Witte T
Br J Haematol; 2010 May; 149(3):376-82. PubMed ID: 20230405
[TBL] [Abstract][Full Text] [Related]
34. Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 Trial.
Burnett A; Cavenagh J; Russell N; Hills R; Kell J; Jones G; Nielsen OJ; Khwaja A; Thomas I; Clark R;
Haematologica; 2016 Jun; 101(6):724-31. PubMed ID: 26921360
[TBL] [Abstract][Full Text] [Related]
35. Pilot study of gemtuzumab ozogamicin (GO), fludarabine, cytarabine and idarubicin combined regimen (GO-FLAI) as first-line induction therapy plus GO alone as consolidation therapy for elderly acute myeloid leukemia patients.
Pirrotta MT; Bocchia M; Bucalossi A; Defina M; Forconi F; Gozzetti A; Lauria F
Acta Haematol; 2007; 118(1):7-9. PubMed ID: 17389781
[No Abstract] [Full Text] [Related]
36. Comparative efficacy and safety of gemtuzumab ozogamicin monotherapy and high-dose cytarabine combination therapy in patients with acute myeloid leukemia in first relapse.
Leopold LH; Berger MS; Cheng SC; Cortes-Franco JE; Giles FJ; Estey EH
Clin Adv Hematol Oncol; 2003 Apr; 1(4):220-5. PubMed ID: 16224410
[TBL] [Abstract][Full Text] [Related]
37. Gemtuzumab ozogamicin: one size does not fit all--the case for personalized therapy.
Ravandi F
J Clin Oncol; 2011 Feb; 29(4):349-51. PubMed ID: 21172885
[No Abstract] [Full Text] [Related]
38. Fractionated administration of gemtuzumab ozogamicin for refractory acute myeloid leukemia.
YAHAGI Y; USUI N; YAMAGUCHI Y; DOBASHI N; YANO S; TAKEI Y; SUGIYAMA K; TAKAHARA S; SAITO T; MINAMI J; KOBAYASHI T; KAMIYAMA Y; MORIKAWA T; AIBA K
Rinsho Ketsueki; 2009 Nov; 50(11):1601-6. PubMed ID: 20009433
[TBL] [Abstract][Full Text] [Related]
39. Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia.
Walter RB; Medeiros BC; Powell BL; Schiffer CA; Appelbaum FR; Estey EH
Haematologica; 2012 May; 97(5):739-42. PubMed ID: 22133771
[TBL] [Abstract][Full Text] [Related]
40. [Treatment of acute myeloid leukaemia without blood transfusion in a member of Jehovah's Witnesses].
Larsen C; Jensen MK
Ugeskr Laeger; 2011 Nov; 173(46):2960-2. PubMed ID: 22094219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
